Likarda
1 October 2025
Likarda Launches "Predictive Polymer Analytics™" — a Breakthrough AI Platform Revolutionizing Complex Therapy Formulation and Encapsulation
Kansas City, MO – October 1, 2025 – Likarda, a global leader in complex therapy formulation for cell and large-molecule therapeutics, today announced the launch of Predictive Polymer Analytics (PPA)™, its next-generation artificial intelligence.....
VIVEbiotech
3 July 2025
VIVEbiotech Appoints Patricio Massera as President
San Sebastián, Gipuzkoa, Spain, July 3, 2025 – VIVEbiotech, a leading Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral vector (LVV) development and manufacturing for in vivo and ex vivo gene and cell therapies, today announced the appointment of...
CellProthera
22 June 2025
CellProthera Collaborator Presents Phase 1/2b Quality-of-Life Results for ProtheraCytes® Cell Therapy at ISTH
Mulhouse, France, June 22, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announces the presentation today of new clinical data by collaborators from Université Paris Cité, demonstrating improvements in health-related quality of life (HRQoL) for patients
Terumo BCT
18 June 2025
Terumo Blood and Cell Technologies Demonstrates Integrated 3-in-1 CAR-T Workflow Using its Quantum Platform
Lakewood, Colorado, June 18, 2025 – Terumo Blood and Cell Technologies, (Terumo BCT), a medical technology company, published a new protocol in a paper demonstrating expanded capabilities for its Quantum™ system to unlock rapid CAR-T cell expansion. The protocol consolidates the processes of T cell
AT3
18 June 2025
Advanced Therapies Think Tank Launches with Powerhouse Faculty Ahead of First Episode on CGT in Community Healthcare
LONDON, UK & WYOMING, US, June 18, 2025 — Advanced Therapies Think Tank (AT3) has unveiled its Season One Faculty ahead of the inaugural episode launching on July 3. With legendary names like Carl June alongside rising voices like Nicole Paulk and Anji Miller, this think tank has been...
eXmoor Pharma
17 June 2025
eXmoor Pharma and Signadori Bio launch partnership to develop next-generation monocyte-based cell therapy for solid tumours
Bristol, UK and Paris, France — 17 June 2025: eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Signadori Bio, a French biotechnology company developing next-generation cancer therapies, today announced a new collaboration to...
Germfree
17 June 2025
King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh
June 17, 2025 - At the BIO International Convention 2025 in Boston, King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC announced a strategic partnership to develop Saudi Arabia’s first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.
ScaleReady
10 June 2025
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
St. Paul, MN (June 10, 2025) – ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability...
Likarda
9 June 2025
Axio BioPharma and Likarda Announce Strategic Partnership to Accelerate Biologic Drug Development and Delivery
MADISON, WI and KANSAS CITY, MO, June 9, 2025 - Axio BioPharma Inc., a next-generation biomanufacturing company using AI to transform mammalian protein production, and Likarda Inc., a leader in advanced drug delivery and formulation technologies, today announced a strategic partnership...
CellProthera
20 May 2025
ERRATUM: CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing
Mulhouse, France, May 20, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its contract development and manufacturing organization (CDMO) partner for its planned Phase 3 trial for ProtheraCytes®, its autologous expanded...
NextCell
20 May 2025
NextCell announces strategic collaboration with Fujifilm Irvine Scientific
Huddinge, Sweden, May 20, 2025 – NextCell Pharma AB ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells (MSCs) and raw materials for the life science sector. The aim of the...
ScaleReady
14 May 2025
ScaleReady awards multiple G-Rex® Grants to leading investigators at the University of Southern California (USC) and the Children's Hospital of Los Angeles (CHLA)
ST. PAUL, Minn., May 14, 2025 - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady announced today three G-Rex Grants that have been awarded to faculty members at the University of Southern California (USC) and the Children's Hospital of...
eXmoor Pharma
13 May 2025
eXmoor Pharma and KU Leuven announce strategic partnership to accelerate cell and gene therapy innovation through new venture
Bristol, UK and Leuven, Belgium — 13 May 2025 - eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, has entered into a strategic partnership with KU Leuven, one of Europe’s leading academic institutions, to support a new cell and gene therapy hub. The...
ReiThera
12 May 2025
ReiThera to Present Five Posters and Introduce New U.S. Business Development Lead at ASGCT 2025
Rome, Italy - May 12 2025 – ReiThera, the Italian CDMO company specialized in the development and manufacturing of genetic vaccines and advanced therapies, is pleased to announce its participation in the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 13–17, 2025, in New Orleans, LA.
Terumo BCT
12 May 2025
Join Parachute implementing Terumo Blood and Cell Technologies’ Rika Plasma Donation System to enhance donor experience and help expand access to lifesaving therapies
Lakewood, Colorado, May 12, 2025 – Terumo Blood and Cell Technologies, (Terumo BCT), a medical technology company, announces that Join Parachute will be adopting the Rika™ Plasma Donation System, a next-generation plasma collection system engineered to streamline plasma collection and prioritize donor comfort.
NextCell
8 May 2025
NextCell CSO Lindsay Davies Honoured with Multiple New Leadership Roles Within European Cell Therapy Community
Huddinge, Sweden, May 8, 2025 – NextCell Pharma AB (“NextCell” or the “Company”), the Scandinavian leader in mesenchymal stromal cell (MSC) therapies, announces its Chief Scientific Officer (CSO), Dr Lindsay Davies, has been named to the Board of Advisors of Advanced Therapies Europe, and...
BCAR
7 May 2025
America’s Blood Centers Joins Blood and Cells Advocacy Roster’s (BCAR) Think-Tank Consortium
Washington, DC and Wyoming, MAY 7, 2025 – America’s Blood Centers (ABC), the national organization of community-based, independent blood centers that supply 60 percent of the nation’s blood supply, today announced that it has joined the Blood and Cells Advocacy Roster (BCAR). BCAR is an...
Title 21
6 May 2025
Title21 Names Advisory Committee to Build Cell Therapy Expertise
Phoenix, AZ, May 6, 2025 – Title21 Health Solutions, the software innovators for meeting life science regulatory needs, has named its inaugural Advisory Committee featuring five leaders from the cell and gene therapy (CGT) space, who bring a breadth of leadership, clinical, and entrepreneurial experience to support the company’s growth.
CellProthera
30 April 2025
CellProthera to Present ProtheraCytes® Clinical Data and Receive a Stem Cell Engineering Abstract Award for Phase I/IIb Results at ISCT 2025 Scientific Annual Meeting in New Orleans
Mulhouse, France, April 30, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, will be presenting two oral abstracts at International Society for Cell & Gene Therapy (ISCT) 2025 New Orleans on May 8 stemming from the recently completed Phase 1/2b EXCELLENT trial for the company’s lead therapy...
Likarda
22 April 2025
Likarda Announces Peer-Reviewed Publication Highlighting Hydrogel Encapsulation with CSS Can Overcome Major Obstacle of Liver Cell Therapies
Kansas City, MO, April 22, 2025 – Likarda, a leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics, announced a new peer-reviewed publication that demonstrates a promising improvement in the effort to develop liver cell-based therapies for patients with....
Terumo BCT
16 April 2025
Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer
LAKEWOOD, Colorado, — April 16, 2025 — Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, today announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments. Daly joins Terumo BCT with over 30 years of business and healthcare industry experience....
Phacilitate
7 April 2025
Registration now open for Advanced Therapies Europe 2025 – where innovation meets opportunity
London, UK, April 7, 2025 – Phacilitate is pleased to announce that registration is now open for Advanced Therapies Europe 2025, 2–4 September at the Hotel Arts, Ritz-Carlton, in Barcelona, one of Europe’s fastest-growing biotech hubs. This exclusive gathering brings together 500 pre-approved leaders from across the advanced therapies ecosystem for three days of high-impact content, curated networking and strategic deal-making.
Title 21
2 April 2025
Title21 Health Solutions Names Jonathan Wofford Chief Commercial Officer
Phoenix, AZ, April 2, 2025 – Title21 Health Solutions, the software innovators for meeting life science regulatory needs, announced the addition of Jonathan Wofford as the company’s first Chief Commercial Officer (CCO) to oversee the company’s products, sales, and marketing efforts. Wofford has over two decades of experience in the cell therapy and stem....
CellProthera
27 March 2025
CellProthera Announced New Board of Directors: Capabilities to Enhance Development and Commercialization Plan
Mulhouse, France, March 27, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, named its new Board of Directors led by co-founder Jérôme Koch, in line with recent bridge financing organized among shareholders and new investors. The new board features both investors and independent members, with a wealth....
Terumo BCT
18 March 2025
Terumo Blood and Cell Technologies Partners with South Korea’s KBIOHealth to Help Develop Nation’s Cell and Gene Therapy Workforce
Lakewood, Colorado, March 18, 2025 – Terumo Blood and Cell Technologies, (Terumo BCT), a medical technology company, signed a memorandum of understanding (MOU) with Osong Medical Innovation Foundation (KBIOHealth) toward joint development of workforce training for cell and gene therapy (CGT) manufacturing. The partners will begin
Terrapinn
14 March 2025
IB Communications Partners with Terrapinn for Advanced Therapies Congress in London
London, UK; March 14, 2025 - IB Communications, an international media relations and public strategy firm, and Terrapinn, a global company whose events promote innovation and technology that changes people’s lives, today announce a partnership to increase audience reach of the life sciences community for the content for Advanced Therapies UK 2025....
Likarda
12 March 2025
Likarda Receives Grant to Deliver Antibody-Secreting Cell Therapy with CSS® Hydrogel Encapsulation
Kansas City, MO, March 12, 2025 – Likarda, a leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics, announced a new grant from the Gates Foundation that supports the company’s proprietary Core-Shell Spherification® (CSS®) system to extend th....
ReiThera
12 March 2025
ReiThera to Unveil ReiCell-AAV Platform for High-Efficiency Gene Therapy AAV Production, Adding to MVA and GRAd Vector Capabilities
Rome, Italy – March 12 2025 – ReiThera, a global Contract Development and Manufacturing Organization (CDMO), is highlighting its latest vector platform, ReiCell-AAV, alongside the rest of its comprehensive portfolio at Advanced Therapies 2025 in London. ReiCell-AAV enables scalable production of AAVs, the most common vector used in commercial....
CellProthera
11 March 2025
CellProthera Presenting at Advanced Therapies Congress 2025 in London
Ibon Garitaonandia, CellProthera's CSO, will present on “Development of cell-based therapies for Post-acute Myocardial Infarction.”
Mulhouse, France, March 11, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announced it will be presenting next week at Terrapinn’s Advanced Therapies Congress 2025, held in London. Ibon Garitaonandia, PhD, MBA, Chief Scientific Officer, will present on “Development of cell-based therapies for Post-acute .....
Minoryx
5 March 2025
Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study)
Barcelona, Spain – 5 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study has been dosed with leriglitazone. TREE is a phase 2a clinical study assessing the safety and efficacy of lead candidate leriglitazone, a novel, brain-penetrant and selective PPAR gamma agonist, to treat patients with Rett syndrome.
Pragmatrix
26 February 2025
Pragmatrix Technology Partners with Achieve Clinics to Transform Cell Therapy Workflows with the PragLife Platform
Chicago, IL, February 26, 2025 – Pragmatrix Technology (“Pragmatrix”), a pioneer in SaaS solutions for the cell therapy industry, proudly announces its partnership with Achieve Clinics (“Achieve”), a Los Angeles, California biotechnology company dedicated to improving patient access to autologous cell therapies. A customized version of PragLife, Pragmatrix’s flagship platform, will now be implemented to support Achieve Clinics' operations end-to-end.
Terumo BCT
25 February 2025
National Alliance of Sickle Cell Centers and Terumo Blood and Cell Technologies Working Together to Improve Outcomes for Patients with Sickle Cell Disease
Lakewood, Colorado, February 25, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, announced a partnership with the nonprofit National Alliance of Sickle Cell Centers (NASCC) that aims to improve the lives of people with sickle cell disease (SCD) by addressing gaps in access to blood transfusion therapy and helping....
Green Elephant Biotech
13 February 2025
Working together for a sustainable future: Bürkert Fluid Control Systems and Green Elephant Biotech
Bürkert Fluid Control Systems has taken a stake in Green Elephant Biotech as a strategic investor so the two companies can work together to develop more efficient, flexible and sustainable cell cultivation processes in the pharmaceutical and....
Terumo BCT
29 January 2025
Carter BloodCare First to Complete the Transition to Automated Whole Blood Processing With Terumo Blood and Cell Technologies
Lakewood, Colorado, January 29, 2025 – Terumo Blood and Cell Technologies, a global leader in blood management solutions, today announces that Carter BloodCare is the first U.S. adopter of its Reveos™ Automated Blood Processing System and Lumia™ Software Platform. Carter BloodCare, one of the largest Texas blood centers, is the first to begin....
ReiThera
24 January 2025
Reithera and Sillajen Partnership Announced
Rome, Italy January 24th 2025 – ReiThera is proud to announce a new partnership with SillaJen through a comprehensive Master Service Agreement (MSA), which establishes ReiThera as the manufacturing partner for SillaJen’s innovative anticancer virus platform, the SJ-600 series.....
Phacilitate
22 January 2025
Phacilitate Awards Katherine High with the 2025 Lifetime Achievement Award at the Advanced Therapies Awards Ceremony in Dallas
London, UK, January 22, 2025 – Phacilitate, a leading brand that connects advanced therapies industry leaders through inspiring conferences, vibrant communities and market intelligence, today presented Katherine A. High, M.D. with its prestigious Lifetime Achievement Award for 2025. Dr. High, who is now President of Therapeutics at AskBio, has had....
Terumo BCT
21 January 2025
Terumo Blood and Cell Technologies Highlights the Future of Blood in DAVOS Interviews 2025 Film Series
Lakewood, Colorado, January 21, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, believes the future of medicine begins with a single drop of blood. From lifesaving blood transfusions to novel personalized therapies, blood and cells are the foundation of healthcare innovation......
Catalent
21 January 2025
Catalent Announces Collaboration with Galapagos to Further Expand Galapagos’ Decentralized CAR-T Manufacturing Network in the U.S.
January 21 2025 – SOMERSET, NJ – Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a biotechnology company with operations in the U.S. and Europe, to support decentralized manufacturing for clinical studies....
Terumo BCT
14 January 2025
Terumo Blood and Cell Technologies and FUJIFILM Irvine Scientific Collaborate to Accelerate T Cell Expansion for Cell Therapy Developers
Lakewood, COLO. AND SANTA ANA, CALIF., January 14, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), and FUJIFILM Irvine Scientific have announced a strategic collaboration to help accelerate T cell expansion using Fujifilm's PRIME-XV® T Cell Expansion Media on Terumo BCT’s Quantum Flex™ Cell Expansion System. By using systems that work together, this collaboration offers an optimized workflow solution with a ready-to-use process, aimed at reducing the barriers in scaling T cell expansion.





